Tagged with VAT

Switzerland Philippe Held, founder of the innovative Swiss medtech Dermosafe, discusses the origins behind the company’s game-changing digitalized solutions for detecting skin cancer at an early stage, how the rollout of the technology is progressing, and the importance of patient and physician education. You founded DermoSafe around five years ago with…

Canada Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for Canada to move away from a ‘silo-ed’ approach to healthcare spending, the value that Astellas has been bringing to patients…

Austria Dr. Dietmar Katinger, CEO of Polymun, an Austrian R&D and contract manufacturing company, discusses the challenges CMO companies face within the Austrian market and increasing industry regulations. He also provides an overview of Austria’s ability to accelerate its stature as an innovation hub. Could you introduce the scope of the…

Colombia Sandra Ramirez, General Manager of Bristol-Myers Squibb Colombia & Mexico, reveals valuable insights into the long-standing presence of BMS in Colombia, marked by a continuous dedication to increase access to medicine, the gradual development of their immuno-oncology pipeline and the creation of an inclusive culture formed by satisfied employees. Ms.…

Bulgaria Deyan Denev, Executive Director of the Association of the Research-Based Pharmaceutical Manufacturers in Bulgaria (ARPharM), shares a clear overview of the role of innovative pharmaceutical players within Bulgaria, and the association’s commitment to working with government to enlarge patients’ access to innovative medicines. How has the overall situation for innovative…

Austria Karl Peter Schwarz, general manager of the Austrian affiliate of LEO Pharma, an ambitious Danish company leading the way in innovative dermatology treatments, provides an in-depth look into how global partnerships and acquisitions have impacted the strategies and operations of the Austrian affiliate. Equally, he provides an insight into how…

Austria Ard van der Meij, country president of Novartis Group Austria, the nation’s leading pharmaceutical company, discusses the advantages in Austria for innovative companies and the steps required to bolster the generics and biosimilars market share within the Austrian market to create a sustainable healthcare ecosystem for the long-term. Furthermore, he…

Canada Professor Rémi Quirion, chief scientist of Québec, discusses his mandate, encourages interprovincial collaboration between Ontario and Québec in the life sciences sector and explains the importance of engaging with civil society through social media to promote the value of research. Rémi, your position might be considered rather unique and niche.…

Austria Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the challenges facing the entire Austrian healthcare system today. Furthermore, he provides solutions to create a sustainable future for Austrian healthcare,…

Canada Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed and modernized pharmaceutical framework agreement between industry and government, and the strong business case Canada needs to make in order…

Canada Lyndal Walker of Ipsen Canada discusses the opportunities present in the Canadian pharma market for a mid-cap innovator like Ipsen, the value of Canada’s research ecosystem, and emerging healthcare trends within the country. Lyndal, you established Ipsen’s Canadian affiliate in 2015. First and foremost, what opportunity did Ipsen globally see…

Austria Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing as Austria capitalizes on its ideal central European location and impressively educated workforce. “From a biotech perspective, [Austria] has a…